| Ticker | ENOB |
|---|---|
| ISIN | US29350E2037 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | $32.915.951 |
| Beta | 0,53 |
| Sitio web | https://renovarogroup.com |
| CEO | David H. Weinstein |
| Fecha de IPO | 07/02/2018 |
| País | US |
| Dirección | 2080 Century Park East, Los Angeles, CA, 90067 |
| Volumen | 808.780 |
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
El precio actual de Enochian Biosciences, Inc. (ENOB) es de 1,42, con una variación del 0,00%.
Enochian Biosciences, Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones